To evaluate the efficacy and safety of Romiplostim N01 combined with non-cryopreserved PBSCs in enhancing platelet recovery after ASCT compared to historical controls receiving cryopreserved PBSCs and rhTPO alone.
Key Findings:
Platelet engraftment occurred significantly earlier in the Romiplostim N01 cohort (median 11 vs. 13 days; P = 0.008).
Complete platelet recovery by day +30 was higher in the Romiplostim N01 group (100% vs. 66.7%; P = 0.027).
Total hospitalization cost was significantly lower with Romiplostim N01 (77,609 ± 21,624 CNY vs. 106,188 ± 14,910 CNY; P < 0.001).
Neutrophil recovery, transfusion requirements, and hospitalization duration were comparable between groups (P values needed for neutrophil recovery).
Safety profiles, treatment responses, and survival outcomes were similar across both groups.
Interpretation:
Romiplostim N01 effectively accelerates platelet recovery and reduces hospitalization costs in ASCT patients using non-cryopreserved PBSCs, suggesting a viable supportive care strategy that could improve patient outcomes.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the reliability of the findings.
Limited sample size may restrict the generalizability of findings to broader populations.
Lack of long-term follow-up data on outcomes limits the understanding of the durability of the treatment effects.
Conclusion:
Romiplostim N01 combined with non-cryopreserved PBSCs is a safe and cost-effective approach to enhance thrombopoietic recovery in ASCT for plasma cell disorders.
